Protagonist Therapeutics, Inc. Share Price
Stocks
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 24/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 138.43 USD | -0.79% |
|
+7.52% | +58.50% |
| 23/10 | UK approves J&J's oral psoriasis pill | RE |
| 12/10 | UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target | MT |
| Market Cap | 895.76Cr 799.91Cr 738.96Cr 669.67Cr 1.25TCr 85TCr 1.27TCr 8.89TCr 3.52TCr 45TCr 3.36TCr 3.29TCr 1,40500Cr | P/E 2026 * |
29.8x | P/E 2027 * | -457x |
|---|---|---|---|---|---|
| Enterprise Value | 843.07Cr 752.86Cr 695.5Cr 630.28Cr 1.18TCr 80TCr 1.2TCr 8.37TCr 3.31TCr 42TCr 3.16TCr 3.1TCr 1,32200Cr | EV / Sales 2026 * |
15.4x | EV / Sales 2027 * | 39.3x |
| Free-Float |
97.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PTGX | Delayed | |
CBOE
| PTGX | Real-time | |
|
Tradegate
| PGF | Real-time |
Last Transcript: Protagonist Therapeutics, Inc.
| 1 day | -0.79% | ||
| 1 week | +7.52% | ||
| Current month | -1.75% | ||
| 1 month | +0.79% | ||
| 3 months | +1.70% | ||
| 6 months | +38.43% | ||
| Current year | +58.50% |
| 1 week | 128.01 |  | 141.85 |
| 1 month | 126.39 | | 152.18 |
| Current year | 77 | | 160.81 |
| 1 year | 74.02 | | 160.81 |
| 3 years | 13.75 | | 160.81 |
| 5 years | 6.91 | | 160.81 |
| 10 years | 4.47 | | 160.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 01/12/2008 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 18/04/2022 |
Venkat Thalladi
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 01/12/2008 |
Harold Selick
CHM | Chairman | 71 | 19/03/2014 |
William Waddill
BRD | Director/Board Member | 69 | 01/07/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 30/09/26 | Exercice | Chief Financial Officer | 1,75,887 | 0.2718% | ||
| 10/09/26 | Exercice | Chief Executive Officer | 21,834 | 0.0337% | ||
| 03/09/26 | Don | Chief Executive Officer | -510 | 0.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.79% | +7.52% | +84.92% | +871.44% | 895.76Cr | |
| +2.41% | +0.29% | +39.41% | +72.14% | 6.47TCr | |
| -0.15% | +7.50% | +11.42% | +71.27% | 5.48TCr | |
| +0.57% | +4.60% | +7.71% | +90.93% | 5.35TCr | |
| +0.37% | +4.67% | +26.68% | +49.64% | 4.6TCr | |
| -1.21% | +2.32% | +21.50% | +118.33% | 4.29TCr | |
| -0.37% | +5.07% | +243.23% | +789.58% | 4.01TCr | |
| +0.05% | +0.21% | +18.06% | +48.50% | 3.35TCr | |
| +1.19% | -4.98% | +26.31% | -0.76% | 2.4TCr | |
| -0.38% | +5.68% | +38.39% | +28.35% | 2.37TCr | |
| Average | +0.17% | +2.92% | +51.76% | +213.94% | 3.92TCr | |
| Weighted average by Cap. | +0.36% | +2.84% | +46.91% | +159.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 55Cr 49Cr 45Cr 41Cr 77Cr 5.21TCr 78Cr 545.03Cr 215.78Cr 2.73TCr 206.04Cr 201.66Cr 8.61TCr | 22Cr 19Cr 18Cr 16Cr 30Cr 2.05TCr 31Cr 213.92Cr 85Cr 1.07TCr 81Cr 79Cr 3.38TCr |
| Net income | 33Cr 29Cr 27Cr 24Cr 46Cr 3.1TCr 46Cr 323.83Cr 128.21Cr 1.62TCr 122.42Cr 119.82Cr 5.12TCr | -1.84Cr -1.64Cr -1.51Cr -1.37Cr -2.57Cr -174.25Cr -2.61Cr -18Cr -7.21Cr -91Cr -6.89Cr -6.74Cr -287.82Cr |
| Net Debt | -53Cr -47Cr -43Cr -39Cr -74Cr -5TCr -75Cr -523.08Cr -207.09Cr -2.62TCr -197.74Cr -193.54Cr -8.26TCr | -49Cr -44Cr -41Cr -37Cr -69Cr -4.69TCr -70Cr -490.61Cr -194.24Cr -2.46TCr -185.47Cr -181.53Cr -7.75TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | $138.43 | -0.79% | 4,09,356 |
| 22/26/22 | $139.53 | +1.05% | 4,04,387 |
| 21/26/21 | $138.08 | +0.07% | 9,90,174 |
| 20/26/20 | $137.99 | +2.64% | 7,74,484 |
| 19/26/19 | $134.44 | +4.42% | 6,54,178 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PTGX Stock
Select your edition
All financial news and data tailored to specific country editions
